Asthma | Unmet Need | US/EU | 2016

Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease in mild asthmatics, unmet needs exist in treating moderate to severe disease. According to the insights of surveyed U.S. and European pulmonologists, greater reduction in exacerbation rate and greater improvement in quality of life are key areas of unmet need for moderate to severe asthma. Furthermore, novel agents with strong efficacy in reducing the rate of exacerbations will have considerable influence on physician prescribing decisions as competition among pharmacological agents rapidly increases in the moderate to severe asthma market.

Login to access report

launch Related Market Assessment Reports